Fig. 01 -

Title Slide

Fig. 02 -

Disclosures

Fig. 03 -

Costs and Opportunities

Fig. 04 -

T1 HG

Fig. 05 -

Aggressive Disease

Fig. 06 -

Very Heterogeneous

Fig. 07 -

Bladder Tumors

Fig. 08 -

Smoking

Fig. 09 -

Step 1

Fig. 10 -

Meta-Analysis

Fig. 11 -

Understaging

Fig. 12 -

Muscularis Propria

Fig. 13 -

Quality Problem

Fig. 14 -

Margins of Resection

Fig. 15 -

Checklist

Fig. 16 -

Disadvantages

Fig. 17 -

En Bloc Devices

Fig. 18 -

The Promise

Fig. 19 -

Recurrence

Fig. 20 -

Step 2

Fig. 21 -

Step 3

Fig. 22 -

EORTC Risk Tables

Fig. 23 -

Independent Predictors

Fig. 24 -

Visualisation Techniques

Fig. 25 -

Photodynamic Diagnosis

Fig. 26 -

PDD Facilitates

Fig. 27 -

PDD and Recurrence

Fig. 28 -

Comparative Effectiveness

Fig. 29 -

PDD and Progression

Fig. 30 -

Narrow Band Imaging

Fig. 31 -

Prognostic Value

Fig. 32 -

Variant Histology

Fig. 33 -

Challenges

Fig. 34 -

Micropapillary Variant

Fig. 35 -

Sarcomatoid Carcinoma

Fig. 36 -

Plasmacytoid Variant

Fig. 37 -

Small Cell Carcinoma

Fig. 38 -

First Determination

Fig. 39 -

Risk Assessment

Fig. 40 -

Prognostic Factors

Fig. 41 -

Treated Safely

Fig. 42 -

EORTC 30962

Fig. 43 -

High Risk

Fig. 44 -

BCG Failures

Fig. 45 -

When To Stop

Fig. 46 -

Recurrences after BCG

Fig. 47 -

Radical

Fig. 48 -

Comparative Retrospective

Fig. 49 -

ERC vs BCG

Fig. 50 -

Immediate vs non immediate

Fig. 51 -

IC vs BCG

Fig. 52 -

When?

Fig. 53 -

Phase 3

Fig. 54 -

Secondary Objectives

Fig. 55 -

Nature Article

Fig. 56 -

Is One Sufficient

Fig. 57 -

Molecular Framework

Fig. 58 -

Conclusions